<code id='A3EF2A9101'></code><style id='A3EF2A9101'></style>
    • <acronym id='A3EF2A9101'></acronym>
      <center id='A3EF2A9101'><center id='A3EF2A9101'><tfoot id='A3EF2A9101'></tfoot></center><abbr id='A3EF2A9101'><dir id='A3EF2A9101'><tfoot id='A3EF2A9101'></tfoot><noframes id='A3EF2A9101'>

    • <optgroup id='A3EF2A9101'><strike id='A3EF2A9101'><sup id='A3EF2A9101'></sup></strike><code id='A3EF2A9101'></code></optgroup>
        1. <b id='A3EF2A9101'><label id='A3EF2A9101'><select id='A3EF2A9101'><dt id='A3EF2A9101'><span id='A3EF2A9101'></span></dt></select></label></b><u id='A3EF2A9101'></u>
          <i id='A3EF2A9101'><strike id='A3EF2A9101'><tt id='A3EF2A9101'><pre id='A3EF2A9101'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:leisure time    Page View:5
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In